MRNA vs. SGEN, AMGN, GILD, BIIB, BNTX, ARGX, NBIX, TECH, QGEN, and RGEN
Should you be buying Moderna stock or one of its competitors? The main competitors of Moderna include Seagen (SGEN), Amgen (AMGN), Gilead Sciences (GILD), Biogen (BIIB), BioNTech (BNTX), argenx (ARGX), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Qiagen (QGEN), and Repligen (RGEN). These companies are all part of the "medical" sector.
Moderna (NASDAQ:MRNA) and Seagen (NASDAQ:SGEN) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, community ranking, risk, earnings, profitability, analyst recommendations and valuation.
Moderna currently has a consensus target price of $126.46, suggesting a potential downside of 11.29%. Seagen has a consensus target price of $229.00, suggesting a potential upside of 0.11%. Given Seagen's higher possible upside, analysts clearly believe Seagen is more favorable than Moderna.
In the previous week, Moderna had 38 more articles in the media than Seagen. MarketBeat recorded 39 mentions for Moderna and 1 mentions for Seagen. Moderna's average media sentiment score of 0.49 beat Seagen's score of 0.00 indicating that Moderna is being referred to more favorably in the media.
Seagen has lower revenue, but higher earnings than Moderna. Seagen is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.
Seagen received 554 more outperform votes than Moderna when rated by MarketBeat users. Likewise, 62.12% of users gave Seagen an outperform vote while only 57.77% of users gave Moderna an outperform vote.
Moderna has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500. Comparatively, Seagen has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500.
Seagen has a net margin of -32.61% compared to Moderna's net margin of -115.82%. Moderna's return on equity of -20.10% beat Seagen's return on equity.
75.3% of Moderna shares are owned by institutional investors. Comparatively, 84.3% of Seagen shares are owned by institutional investors. 15.7% of Moderna shares are owned by company insiders. Comparatively, 25.9% of Seagen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Moderna and Seagen tied by winning 9 of the 18 factors compared between the two stocks.
Get Moderna News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MRNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
